Jasper Therapeutics, Inc. 8-K

What Happened Jasper Therapeutics, Inc. announced on March 30, 2026 that it issued a press release reporting its financial results for the quarter and year ended December 31, 2025 and providing a corporate update. The press release was furnished as Exhibit 99.1 to the Current Report on Form 8‑K (Item 2.02). The company noted the information is furnished — not “filed” — under the Exchange Act per Form 8‑K instructions.

Key Details

• Date of announcement: March 30, 2026.
• Reporting period: quarter and year ended December 31, 2025.
• Press release containing earnings and corporate update is furnished as Exhibit 99.1 to the 8‑K.
• The disclosure is furnished (Item 2.02) and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into other filings (per Item 9.01 language).

Why It Matters This 8‑K signals Jasper’s public release of its latest quarterly and full‑year financial results and a corporate update — material information investors use to assess revenue, earnings, guidance, and business progress. Retail investors should read the Exhibit 99.1 press release for the specific figures and commentary; note the company expressly furnished (rather than filed) the release, which affects legal disclosure treatment but not the substance of the reported results.